RCKT analyst estimates

Rocket Pharmaceuticals (RCKT) analyst ratings, the average price target and its range, and every firm's latest call.

RCKT analyst ratings and price targets

DateFirmCallTarget
Oct 8, 2026Goldman SachsRocket Pharmaceuticals upgraded to Neutral from Sell at Goldman Sachs$4.00
Oct 7, 2026JefferiesRocket Pharmaceuticals (RCKT) PT Lowered to $2.95 at Jefferies$2.95
Sep 16, 2026NeedhamRocket Pharmaceuticals upgraded to Buy from Hold at Needham$9.00
Jan 8, 2026Morgan StanleyRocket Pharmaceuticals price target lowered to $5 from $7 at Morgan Stanley$5.00
Oct 3, 2025Leerink PartnersRocket Pharmaceuticals price target lowered to $7 from $9 at Leerink$7.00
May 28, 2025JefferiesThese Analysts Slash Their Forecasts On Rocket Pharmaceuticals$2.50
May 28, 2025Goldman SachsGoldman downgrades Rocket to Sell on 'surprising and concerning' update$2.00
Dec 30, 2024WedbushRocket Pharmaceuticals initiated with an Outperform at Wedbush$32.00
Nov 11, 2024Canaccord GenuityRocket Pharmaceuticals (RCKT) PT Raised to $39 at Canaccord Genuity$39.00
Sep 18, 2024Canaccord GenuityCanaccord Genuity Reiterates Buy Rating on Rocket Pharmaceuticals (RCKT)$38.00
Sep 17, 2024Morgan StanleyMorgan Stanley on Rocket Pharmaceuticals (RCKT): 'we are encouraged by rapid enrollment'$45.00
Apr 2, 2024Goldman SachsGoldman Sachs Starts Rocket Pharmaceuticals (RCKT) at Neutral, 'Four Potential Launches in Next 2Y but DD Oppy May be Overstated'$39.00
Oct 3, 2022Raymond JamesRaymond James Maintains Outperform on Rocket Pharmaceuticals, Raises Price Target to $34$34.00
Aug 9, 2022Raymond JamesRaymond James Maintains Outperform on Rocket Pharmaceuticals, Raises Price Target to $24$24.00
Aug 12, 2021UBSRocket Pharmaceuticals (RCKT) PT Lowered to $69 at UBS$69.00